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O-GlcNAcylation of G6PD promotes the pentose
phosphate pathway and tumor growth
Xiongjian Rao1,2,*, Xiaotao Duan3,*, Weimin Mao4,*, Xuexia Li1, Zhonghua Li1,2, Qian Li1, Zhiguo Zheng4,
Haimiao Xu4, Min Chen5, Peng G. Wang5,6, Yingjie Wang2,7, Binghui Shen8 & Wen Yi1,2
The pentose phosphate pathway (PPP) plays a critical role in macromolecule biosynthesis
and maintaining cellular redox homoeostasis in rapidly proliferating cells. Upregulation of the
PPP has been shown in several types of cancer. However, how the PPP is regulated to confer
a selective growth advantage on cancer cells is not well understood. Here we show that
glucose-6-phosphate dehydrogenase (G6PD), the rate-limiting enzyme of the PPP, is
dynamically modiﬁed with an O-linked b-N-acetylglucosamine sugar in response to hypoxia.
Glycosylation activates G6PD activity and increases glucose ﬂux through the PPP, thereby
providing precursors for nucleotide and lipid biosynthesis, and reducing equivalents for
antioxidant defense. Blocking glycosylation of G6PD reduces cancer cell proliferation in vitro
and impairs tumor growth in vivo. Importantly, G6PD glycosylation is increased in human lung
cancers. Our ﬁndings reveal a mechanistic understanding of how O-glycosylation directly
regulates the PPP to confer a selective growth advantage to tumours.
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A
ltered metabolism is a key characteristic of cancer cells.
The metabolic ﬂux in cancer cells is markedly repro-
grammed to provide elevated amounts of building blocks
for anabolic biosynthesis of macromolecules during rapid cell
growth and proliferation1,2. In addition, cancer cells often possess
enhanced capability to regulate redox homoeostasis to protect
against oxidative stress in the tumor microenvironment3,4.
However, the molecular mechanisms by which cancer cells
sense metabolic signal to couple anabolic synthesis and redox
homoeostasis to promote cancer cell proliferation and cell
survival are not well understood.
Glucose ﬂux through the glycolytic pathway can be diverted
into the pentose phosphate pathway (PPP). The PPP plays a vital
role in meeting the cellular demands for anabolic biosynthesis
and providing anti-oxidative defense5. It generates ribose-6-
phosphate for de novo synthesis of DNA and RNA, and the
reducing equivalent reduced NADPH for reductive biosynthesis
of lipids. NAPDH also functions as an important antioxidant for
detoxiﬁcation of high levels of reactive oxygen species (ROS)
produced during rapid cell proliferation to promote cell survival.
Activity of the PPP is known to be upregulated in cancer cells
compared with normal epithelial cells6. Knocking down of key
enzymes in the PPP inhibits tumor growth and sensitizes cancer
cells to oxidative stress7,8. Glucose-6-phosphate dehydrogenase
(G6PD) catalyses the ﬁrst committed and rate-limiting step of the
PPP. It catalyses the oxidation of G6P to 6-phosphogluconate and
produces NADPH in the presence of NADPþ . G6PD is
considered the pacesetter of the PPP and the primary control
point for NADPH production. G6PD activity is subjected to
various regulatory mechanisms ranging from transcription to
translation, further illustrating its importance in regulating
cellular metabolism5.
O-linked b-N-acetylglucosamine (O-GlcNAc) is a dynamic
and inducible post-translational modiﬁcation of serine and/or
threonine residues of nuclear and cytosolic proteins9. In cells,
a single set of antagonistic enzymes—O-GlcNAc transferase
(OGT) and O-GlcNAc hydrolase are responsible for the
addition and removal of GlcNAc moiety, respectively.
O-GlcNAcylation has been identiﬁed in numerous proteins and
shows a complex crosstalk with protein phosphorylation10.
Increasing evidence has shown that O-GlcNAcylation serves
important roles in regulating gene transcription, cellular
signalling and stress responses11. Generally considered as a
‘nutrient sensor’ of cells, recent ﬁndings also indicate that
O-GlcNAcylation may actively and directly participate in
regulating cellular metabolism12. O-GlcNAc levels are signi-
ﬁcantly elevated in various cancers. Aberrant O-GlcNAcylation
has been shown to correlate with cancer cell proliferation,
invasion and metastasis both in vitro and in vivo13–15.
Thus, deregulation of O-GlcNAcylation appears to be a general
feature of cancer cells. However, the detailed mechanisms
by which protein-speciﬁc O-GlcNAcylation contributes to
cancer metabolic reprogramming and tumorigenesis remain
largely unknown.
Here, we present evidence that O-GlcNAcylation of G6PD
coordinates cancer cell anabolic biosynthesis and redox homo-
eostasis to promote tumor growth in vivo. Mechanistically,
glycosylation activates G6PD activity and increases glucose ﬂux
through the PPP, thereby generating precursors for nucleotide
and lipid biosynthesis, and reducing equivalents for antioxidant
defense. In addition, glycosylation of G6PD promotes cancer cell
proliferation in vitro and tumor growth in vivo. Importantly,
G6PD glycosylation is elevated in human lung cancers. Thus, our
study identiﬁes a previously unknown mechanism for the
regulation of cancer metabolism and tumor growth by protein
O-glycosylation.
Results
G6PD is dynamically modiﬁed by O-GlcNAc at serine 84.
Previous proteomic studies16,17 have revealed that a large number
of metabolic enzymes including G6PD are modiﬁed by
O-GlcNAc in eukaryotic cells, suggesting a critical role of
O-GlcNAcylation in regulating cell metabolism. To investigate
whether O-GlcNAcylation directly regulates the PPP, we focus
on the rate-limiting enzyme G6PD. To conﬁrm that G6PD
is O-GlcNAcylated, we employed a well-established chemo-
enzymatic labelling approach16. We enzymatically labelled all
O-GlcNAc-modiﬁed proteins from 293T cell lysates with an
azido-N-acetylgalactosamine sugar. Labelled proteins were
then biotinylated via Cu(I)-mediated [3þ 2] azide-alkyne
cycloaddition (CuACC) chemistry and captured with
streptavidin-agarose beads. Subsequent immunoblotting of the
captured proteins with an antibody against G6PD showed strong
O-GlcNAcylation of G6PD (Fig. 1a,b). Calculation of the
glycosylated protein versus total G6PD protein yielded an
estimate of basal glycosylation level to be 8±2.1%.
Glycosylation of G6PD was enhanced by 4.5-fold in cells by
overexpression of OGT, the enzyme responsible for the addition
of O-GlcNAc onto proteins (Fig. 1c). To corroborate with this
result, we immunoprecipitated endogenous G6PD from 293T cell
lysates and immunoblotted with a pan-anti-O-GlcNAc antibody
(CTD110.6), which yielded a distinct signal albeit much lower
sensitivity compared to the chemo-enzymatic approach
(Supplementary Fig. 1). Thus, G6PD is O-GlcNAc-modiﬁed
in cells.
To identify the site(s) of O-GlcNAcylation on G6PD, we
transiently co-expressed Flag-tagged G6PD and OGT in 293T
cells. After immunoprecipitation and in-gel trypsin digestion of
G6PD, peptides were subjected to high-resolution mass spectro-
metry analysis (nanoLC-LTQ-CID/ETD-Orbitrap). We identiﬁed
a single site of O-GlcNAcylation at Serine 84, a highly conserved
residue in homologues proteins among mammals (Fig. 1d and
Supplementary Fig. 2). Mutation of Ser84 to valine abolished the
glycosylation signal, supporting that Ser84 is the only site of
O-GlcNAcylation on G6PD (Fig. 1d). Notably, no other forms of
modiﬁcation such as phosphorylation were detected at the same
serine residue.
Accumulating research data have suggested that protein
O-GlcNAcylation is induced in response to various forms of cell
stress18, and that elevation of O-GlcNAcylation plays an
important role in modulating critical biological pathways to
improve cell survival18. To investigate whether O-GlcNAcylation
of G6PD is dynamically regulated in cells, we subjected cells to
different stress conditions and probed the O-GlcNAcylation levels
of G6PD. Notably, G6PD glycosylation was induced in a time-
dependent manner under hypoxic conditions (3.1- to 4.7-fold
induction, Fig. 1e). We found that hypoxic treatment induced
global O-GlcNAc levels in cells and endogenous OGT expression
(Supplementary Fig. 3A). Consistently, in vitro enzymatic assays
demonstrated that OGT activity in cell lysates was increased
under hypoxia (Supplementary Fig. 3B). Hypoxia is also known
to induce profound changes in glucose metabolism, including
increasing glucose uptake via the transcriptional upregulation of
glucose transporters19. Indeed, the hypoxic treatment
signiﬁcantly enhanced glucose uptake rate in our study
(Supplementary Fig. 3C), nicely correlated with the induction of
O-GlcNAcylation level. In addition, inhibition of glucose uptake
by a small-molecule inhibitor suppressed the induction of G6PD
O-GlcNAcylation under hypoxia (Supplementary Fig. 3D). Thus,
hypoxia induces G6PD glycosylation likely by increasing OGT
expression and cellular glucose concentration, which serves as a
biosynthetic precursor for O-GlcNAc. Similarly, G6PD
glycosylation was also stimulated when cells were treated with
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high glucose concentration (4.2- to 5.8-fold induction), or with
serum (1.7-fold induction; Fig. 1f,g). In agreement with previous
reports3, growth factor (serum) stimulation signiﬁcantly induced
cellular glucose uptake rate in our study (Supplementary Fig. 3E).
Taken together, these results demonstrate that G6PD
O-GlcNAcylation is dynamically regulated in response to
different cellular conditions, suggesting a signalling role of
G6PD glycosylation in cells.
O-GlcNAcylation of G6PD activates enzyme activity. To
understand the biological signiﬁcance of G6PD O-GlcNAcylation,
we ﬁrst examined the effect of O-GlcNAcylation on G6PD enzyme
activity. Enhancing O-GlcNAcylation in 293T cells by OGT over-
expression or pharmacological inhibition of O-GlcNAc hydrolase
with a speciﬁc inhibitor thiamet-G20 signiﬁcantly increased G6PD
enzyme activity by two to fourfold (Fig. 2a). Mutation of S84 to
valine (S84V) retained a similar activity as compared to the wild-
type (WT) G6PD. However, the S84V mutant showed negligible
response in enzyme activity on OGT overexpression or thiamet-G
treatment (Fig. 2a). Similar results were obtained when cells were
subjected to hypoxic treatments to induce G6PD glycosylation
(Supplementary Fig. 4). Thus, these results suggest that S84 is an
important regulatory site of G6PD activity.
To further understand the effect of S84 glycosylation on G6PD
activity, we examined the steady-state kinetics of G6PD with
different glycosylation levels. Speciﬁcally, we compared the
kinetics of Flag-tagged WT G6PD expressed in 293T cells in
the presence or absence of OGT overexpression. Flag-tagged
G6PD with high O-GlcNAcylation displayed substantially higher
catalytic efﬁciency (2.9-fold increase in kcat/Km for NADPþ and
1.4-fold increase for G6P) than Flag-tagged G6PD with low
O-GlcNAcylation (Supplementary Table 1). Notably, the Km for
NADPþ showed about twofold decrease in G6PD with high
glycosylation levels, indicating a higher binding afﬁnity of
NADPþ to the enzyme. Consistently, the calculated dissociation
constant (kd) for NADPþ using the ﬂuorescence titration assay
was 2.6 mM for G6PD with high glycosylation levels, which is
about threefold lower than G6PD with low glycosylation levels
(7.3 mM). Thus, the kinetics study suggests that O-GlcNAcylation
induces G6PD activity likely by enhancing the binding afﬁnity of
NADPþ to G6PD.
The G6PD protein exists in different oligomeric states, ranging
from monomer, dimer, tetramer to hexamer. Studies have shown
that only dimeric and tetrameric forms of G6PD are catalytically
active21,22. To examine whether S84 glycosylation affects
oligomerization states of G6PD, we performed a protein
crosslinking experiment using glutaraldehyde. As shown in
Fig. 2b, enhancing O-GlcNAcylation levels by OGT
overexpression resulted in substantial increased formation of
dimeric G6PD, but not S84V mutant. Control immunoblots were
shown in Fig. 2c. These results suggest that O-GlcNAcylation
activates G6PD in part by perturbing the equilibrium between
different oligomeric forms to favour a higher oligomeric state.
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Figure 1 | G6PD is dynamically modiﬁed by O-GlcNAc at serine 84. (a) Chemoenzymatic labelling approach for biotinylation, capture and detection of
O-GlcNAcylated G6PD from cells. Endogenous O-GlcNAcylated proteins in cell lysates were chemoenzymatically tagged with an azido-galactose sugar
using a mutant galactosyltransferase (GalT, Y289L) and the non-natural nucleotide sugar analogue UDP-GalNAz, and then biotinylated by reaction of the
azido-galactose sugar with an alkyne-functionalized biotin molecule. The biotinylated proteins were pulled down using streptavidin beads, and eluted with
SDS. Lysates before pull down (input) and the captured proteins (elution) were immunoblotted with an antibody towards G6PD. (b) Detection of
O-GlcNAcylated G6PD levels from 293Tcells. Lysates prior to pull down (input) and the captured proteins (elution) were immunoblotted with an antibody
towards G6PD. Control experiments in the absence of GalT or UDP-GalNAz demonstrated selective labelling of the O-GlcNAcylation on G6PD.
(c) Detection of O-GlcNAcylated G6PD levels from 293T cells overexpressing OGT using the chemo-enzymatic method. (d) Peptide sequence and
glycosylation site identiﬁed by LTQ-Orbitrap MS/MS. Glycosylation levels of WT G6PD compared with the S84V mutant expressed in 293T cells as
determined by the chemoenzymatic method. (e) Determination of O-GlcNAcylation levels of G6PD under hypoxic treatment for indicated periods of time
by the chemoenzymatic method. (f) Detection of O-GlcNAcylation levels of G6PD cultured in media with different glucose concentrations by the
chemo-enzymatic method. (g) Detection of O-GlcNAcylation levels of G6PD in A549 cells on serum stimulation by the chemoenzymatic method.
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O-GlcNAcylation of G6PD promotes the PPP. To create a
system to study the effect of G6PD S84 glycosylation on cellular
metabolism, we depleted endogenous G6PD and stably expressed
small hairpin RNA (shRNA)-resistant Flag-tagged WT or S84V
G6PD in A549 lung cancer cells (henceforth referred to as
WT G6PD or S84V G6PD replacement cells, Supplementary
Fig. 5). As the ﬁrst and rate-limiting step of the PPP, induction of
G6PD activity by O-GlcNAcylation is expected to have an impact
on the metabolic ﬂux of the PPP. Indeed, we observed a signi-
ﬁcant increase in ﬂux (B2.1-fold) through the oxidative PPP, as
measured by the amount of released 14CO2 from [1-14C]-glucose,
when OGT was overexpressed in WT G6PD replacement cells. In
contrast, in S84V G6PD replacement cells, PPP ﬂux exhibited a
modest increase on OGT overexpression (Fig. 3a). The
small increase in PPP ﬂux is likely due to the inhibition
of phosphofructokinase 1 (PFK1), a key regulatory enzyme
in glycolysis pathway, by O-GlcNAcylation as shown in the
previous study23. Nevertheless, this result demonstrates that S84
O-GlcNAcylation of G6PD induced glucose ﬂux through the
PPP. This observation was independently veriﬁed by a metabolic
tracing experiment, in which cells were metabolically
labelled with 1,2-13C-glucose and the relative isotopic enrich-
ment accumulation of singly versus doubly 13C-labelled lactate
was measured by liquid chromatography–mass spectrometry
(LC–MS) analysis (Fig. 3b). In addition, we showed that
hypoxia induced similar upregulation in PPP ﬂux and that
the upregulation was dependent on G6PD glycosylation
(Supplementary Fig. 6).
Our previous investigation on O-GlcNAcylation of PFK1 has
demonstrated that O-GlcNAcylation inhibits PFK1 enzyme
activity, resulting in rerouting a portion of glucose ﬂux through
the PPP23. We then carried out experiments to further
understand the differential contribution to PPP regulation by
glycosylation of PFK1 and G6PD. PFK1 has three isoforms
(PFKL, PFKP and PFKM) that show different regulatory response
by O-GlcNAcylation with PFKM being the least responsive23. We
generated A549 stable cell lines that harbour only single isoforms.
In addition, these PFK1 isoforms were mutated to become
glycosylation-deﬁcient (referred to as PFKL-SA, PFKP-SA and
PFKM-SA). Consistent with the previous study, PPP ﬂux
increased signiﬁcantly in cells expressing WT PFK1 isoforms on
OGT overexpression (Supplementary Fig. 7). The expression of
glycosylation-deﬁcient mutants of PFK1 (PFKL-SA or PFKP-SA)
resulted in a large suppression of PPP ﬂux, but the expression of
PFKM-SA mutant only resulted in a modest decrease in PPP ﬂux
(Supplementary Fig. 7). Replacement of WT G6PD with S84V
G6PD further suppressed PPP ﬂux in all three cases. These results
suggest that O-GlcNAcylation regulates the PPP activity through
the coordinated action of PFK1 and G6PD. In cases where PFKL
or PFKP expression is predominant, PFK1 glycosylation exerts
more control in regulating the PPP ﬂux. On the other hand, when
PFKM expression is predominant, G6PD glycosylation plays a
more dominant role in PPP regulation.
To further examine the impact of G6PD glycosylation on
major metabolic pathways, we subjected cell extracts to LC–MS
analysis to determine the relative enrichment of speciﬁc
metabolites. On OGT overexpression, the metabolic proﬁle of
WT G6PD replacement cells demonstrated a general increase in
PPP metabolites, as compared with S84V G6PD replacement cells
(Fig. 3c). Metabolites involved in glycolytic pathway and
tricarboxylic acid cycle showed no signiﬁcant difference between
WT and S84V G6PD replacement cells (Fig. 3d,e). Control
experiments were performed in parental A549 cells on G6PD
overexpression (Supplementary Table 2). The metabolite patterns
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suggested that S84 glycosylation imparted a speciﬁc metabolic
effect on glucose metabolism through the PPP.
G6PD glycosylation promotes cell proliferation and survival.
Rapidly dividing cancer cells require three basic outputs from
metabolism: energy in the form of ATP, building blocks for
macromolecular synthesis and cellular assembly and molecules to
maintain the proper cellular redox environment24. Upregulation
of the PPP ﬂux induced by O-GlcNAcylation of G6PD would
provide cells with pentose sugars for nucleotides and nucleic acid
biosynthesis, as well as reducing equivalents from NADPH for
lipid biosynthesis and to combat oxidative stress. We compared
DNA synthesis in WT G6PD or S84V G6PD replacement
A549 cells under hypoxic conditions using the 5-bromo-2’-
deoxyuridine incorporation assay. DNA synthesis was
signiﬁcantly increased in WT G6PD replacement A549 cells
compared with the S84V mutant replacement cells (Fig. 4a). As a
control, depletion of G6PD with shRNA led to a sharp inhibition
of DNA synthesis. These results are consistent with the previous
observation that hypoxia activates G6PD glycosylation, which
leads to enhanced ﬂux through the PPP for nucleic acid
biosynthesis. Control experiments were carried out under
normoxia (Supplementary Fig. 8). In addition, we found that
S84V mutant replacement cells showed decreased lipogenesis
compared with WT replacement cells under hypoxic conditions
(Fig. 4b). Consistently, WT G6PD replacement cells exhibited
signiﬁcantly higher cell proliferation rate than S84V mutant
replacement cells under both hypoxic and normoxic conditions,
yet with more pronounced effect under hypoxia (Fig. 4c,
Supplementary Fig. 9). As a control, depletion of G6PD in
A549 cells inhibited cell proliferation. Addition of Nuc (four
ribonucleotides and four deoxyribonucleotides) to the culture
medium partially rescued cell proliferation defect in S84V G6PD
replacement cells (Fig. 4c, Supplementary Fig. 9). Thus, these
results suggest that O-GlcNAcylation of G6PD enhances cellular
biosynthesis and promotes cell proliferation.
Consistent with increased glucose ﬂux through the PPP,
enhancing O-GlcNAc levels by OGT overexpression in WT
G6PD replacement cells resulted in 1.8- and 2.6-fold increase in
NADPH and reduced glutathione (GSH) levels, respectively
(Fig. 4d,e). Blocking glycosylation of G6PD signiﬁcantly sup-
pressed the induction of NADPH and GSH, demonstrating the
importance of O-GlcNAc glycosylation at S84 in regulating
NADPH homoeostasis. To further conﬁrm that glycosylation of
G6PD plays an important role in antioxidant defense, we
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measured the sensitivity of A549 replacement cells to ROS
production and ROS-mediated cell death. Induction of ROS levels
by diamide was signiﬁcantly suppressed in WT G6PD replacement
cells as compared with S84V mutant replacement cells (Fig. 4f).
ROS levels were signiﬁcantly induced by hypoxic treatments in a
larger extent in S84V mutant replacement cells (Supplementary
Fig. 10). Consistently, compared with WT replacement cells, S84V
mutant replacement cells were markedly more sensitive to
hydrogen peroxide (H2O2) treatment, and exhibited higher
percentage of ROS-induced cell death (Fig. 4g). Addition of
GSH, the ROS scavenger, to the culture medium partially rescued
cell proliferation defect in S84V G6PD replacement cells (Fig. 4c,
Supplementary Fig. 9). Combination of GSH and Nuc appeared to
augment the rescue effect. These results indicate that G6PD
O-GlcNAcylation plays an important role in regulating redox
homoeostasis to promote cancer cell survival and cell proliferation.
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G6PD glycosylation promotes tumor formation. To gain a
better understanding of the impact of G6PD glycosylation
on cancer development, we ﬁrst examined whether G6PD is
glycosylated in different human solid tumor cells, including
breast cancer cell line, MCF7, lung cancer cell lines, H661 and
A549, ovarian cancer cell line, SKOV-3, melanoma cell line,
A375, and osteosarcoma cell line, U2OS (Supplementary
Fig. 11). G6PD glycosylation was observed in all of these cancer
cell lines even though the glycosylation levels were varied, sug-
gesting that G6PD glycosylation is potentially linked to tumor
pathology.
To determine whether G6PD glycosylation is important for
tumor formation in vivo, we injected WT G6PD or S84V G6PD
replacement A549 cells into immunocompromised mice and
assayed their ability to form tumours. Mice injected with S84V
G6PD replacement cells showed a signiﬁcant delay in tumor
formation compared with mice injected with WT G6PD
replacement cells, producing tumours with much smaller total
mass (Fig. 5a). Western blotting analysis conﬁrmed that Flag-
tagged WT or S84V G6PD proteins were retained in tumours and
that WT G6PD was O-GlcNAcylated in vivo (Supplementary
Fig. 12). These results are consistent with the in vitro cell
proliferation data and demonstrate that glycosylation of
G6PD at S84 provides a critical growth advantage to tumours
in vivo.
G6PD glycosylation is upregulated in lung cancers. Cellular
O-GlcNAcylation is reported to be upregulated in various human
cancers, indicating that targeting O-GlcNAcylation may serve as a
novel anti-cancer strategy25. The ﬁnding that G6PD
O-GlcNAcylation is important for A549 lung cancer cell
proliferation and tumor growth prompted us to examine G6PD
glycosylation in human lung cancers. We obtained a total of 39
pairs of primary human lung cancer tissue samples with matched
adjacent normal lung tissues, and determined the level of
glycosylation by the chemoenzymatic tagging approach and
normalization to G6PD protein levels. Among these samples,
eight pairs showed minimal G6PD expression in either cancer or
normal tissues that prevented reliable quantiﬁcation. Among the
remaining 31 pairs of samples, 16 pairs showed relatively higher
level of glycosylated G6PD in cancer tissues than the matched
normal tissues (Fig. 5b and Supplementary Fig. 13). Quantiﬁ-
cation of these samples conﬁrmed that the increase in the ratio of
glycosylated versus total G6PD proteins is statistically signiﬁcant
(Fig. 5c). Previous studies showed that O-GlcNAcylation and
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Figure 5 | O-GlcNAcylation of G6PD is important for tumor growth in vivo and is increased in human lung cancers. (a) Tumor formation in nude mice
(n¼ 11) injected with WTor S84V G6PD replacement A549 cells. (Left) Dissected tumours after 7 weeks of growth in mice injected with WTreplacement
cells on the right ﬂank and S84V replacement cells on the left ﬂank. (Right) Masses of the dissected tumours. (b) Detection of G6PD O-GlcNAcylation and
OGT expression in human lung tumor (T) tissues and the matching adjacent normal (N) tissues. (c–e) The statistical analysis of 16 paired tumor and
normal samples. Relative G6PD glycosylation level was normalized to the total G6PD protein level for each patient. Statistical analysis was performed by
paired Student’s t-test (*Po0.05, **Po0.01). NS, not signiﬁcant.
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OGT expression were signiﬁcantly elevated in different cancer
tissues compared with the adjacent normal tissues, including lung
cancer13,14. Thus, we further analysed the expression levels of
OGT protein in these samples. Among 31 pairs of samples, 20
pairs showed relatively higher level of OGT expression in cancer
tissues than in the matched normal tissues (Fig. 5b,d,
Supplementary Fig. 14). The samples that showed higher level
of G6PD glycosylation also showed higher level of OGT
expression. Thus, the increased G6PD glycosylation correlates
with the increased OGT expression in lung cancer.
The development of non-small cell lung cancer is often divided
into four stages (I, II, III and IV) based on tumor size and
metastatic features. To determine whether G6PD glycosylation is
associated with lung cancer progression, we analysed the level of
glycosylation in the previous 16 paired samples according to their
stages. The levels of G6PD glycosylation were increased
signiﬁcantly in all stages when compared with the normal tissues
(Fig. 5e). However, there was no signiﬁcant difference in the levels
of glycosylation among different stages (Fig. 5e). Collectively,
these results suggest that G6PD glycosylation may play a role in
lung cancer initiation, but not progression of the disease.
Discussion
Increasing evidence points to pivotal roles for O-GlcNAcylation
in regulating a diverse set of proteins that function in
transcription, insulin signalling and cellular stress response26.
Our studies identify a previously unknown mechanism by which
this modiﬁcation regulates metabolic ﬂux to promote
proliferation and survival of cancer cells. Activation of G6PD
activity via O-GlcNAcylation upregulates glucose ﬂux through
the PPP, leading to increased production of precursors involved
in the biosynthesis of nucleotides. Enhancing ﬂux through the
PPP also provides reducing power in the form of NADPH and
GSH to combat ROS, thereby supporting cell survival under
oxidative stress. The dynamic induction of G6PD glycosylation in
response to hypoxia and nutrient levels and coordination of
metabolic reprogramming for cancer cell proliferation suggest
that O-GlcNAcylation not only serves as a cellular sensor of
metabolic states, but also constitutes a key metabolic regulator of
glucose ﬂux. Our study also provides a new mechanistic insight
into the expanding scope of redox homoeostasis in cells.
It has long been established that the activities of metabolic
enzymes are regulated by small-molecule metabolites. In contrast
to the non-covalent, often transient, interactions of allosteric
modulators, the O-GlcNAcylation is covalent, yet reversible and
dynamically responsive to metabolic status. In addition, unlike
the small molecules UDP-GlcNAc and O-GlcNAc are not
primary or secondary metabolites. This may represent a
difference in the function of O-GlcNAc compared with those
small molecules. Given that many metabolic enzymes have been
recently shown to be acetylated27–29, phosphorylated30,31 and
glycosylated17,23, the post-translational modiﬁcation of metabolic
enzymes may serve as a general mechanism for controlling
cellular metabolism.
Elevated PPP ﬂux has been demonstrated in cancer cells5. In
addition to providing precursors for anabolic biosynthesis and
maintaining cellular redox homoeostasis, elevated PPP activity is
also linked to cancer cell invasion, metastasis and resistance to
cancer therapies. A plethora of mechanisms including activation
of oncogenic signalling pathways and inactivation of tumor
suppressors have been shown to regulate the PPP ﬂux in a tightly
controlled fashion6. More recent studies demonstrate that protein
lysine acetylation positively or negatively regulates activities of
key enzymes in the PPP, providing a selective metabolic
requirement for cell proliferation and cell survival under
oxidative stress32,33. Our ﬁndings that O-GlcNAcylation
positively regulates G6PD activity add a new mechanistic
insight into the regulation of PPP, and suggest that modulating
G6PD activity may represent a potential therapeutic strategy for
cancer.
Methods
Cell culture and tumor tissues. The cell lines 293T, A549, MCF7, H661, SKOV-3,
A375 and U2OS were obtained from ATCC and cultured according to ATCC
protocols. Lung tumor tissues and matching tumor-adjacent normal tissues from
the same patient were obtained from the Zhejiang Cancer Hospital Bio-specimen
Repository (Hangzhou, China). Informed consent was obtained from the patients.
Procedures related to human subjects were approved by the Ethic Committee of
Zhejiang Cancer Hospital.
Immunoblotting. Cells were lysed in SDS lysis buffer (1% SDS, 50mM Tris-HCl,
pH 7.5, 100mM NaCl, and Complete protease inhibitors (Roche)), and the lysate
was resolved on a 4–12% SDS-PAGE gel, transferred to nitrocellulose membrane,
and immunoblotted with the indicated antibodies. Antibodies used in this study
were obtained from the following sources: anti-O-GlcNAc antibody (clone
18B10.C7, Thermo Scientiﬁc, 1:1,000 ﬁnal dilution), anti-G6PD antibody (clone
G12, Santa Cruz Biotechnology, 1:1,000), anti-Flag antibody (clone M2, Sigma-
Aldrich, 1:5,000 ﬁnal dilution) anti-GAPDH antibody (clone G6, Santa Cruz
Biotechnology, 1:1,000 ﬁnal dilution). All protein concentrations were measured
using the Bicinchoninic Acid protein assay (Pierce). Western blots were visualized
and quantiﬁed using an Odyssey Infrared Imaging System (LI-COR Biosciences,
Version 2.1). The uncropped blots for main ﬁgures were presented in
Supplementary Figs 15 and 16.
Generation of stable cell lines. To generate the G6PD rescue A549 cell lines,
Flag-tagged WT G6PD (cDNA clone obtained from Origene) and S84V G6PD
were cloned into the expression vector pLenti-FlagN-shRNA34. This vector allows
for expression of an exogenous gene with the simultaneous knockdown of the
endogenous gene. To knockdown endogenous G6PD, the shRNA sequence
50-CCGGGCTGATGAAGAGAGTGGGTTTCTCGAGAAACCCACTCTCTTC
ATC-AGCTTTTTG-30 (obtained from the Public TRC Portal database) or the
corresponding scramble sequence 50-CCGGTCCTAAGGTTAAGTCGCCCTCG
CTCGAGCGAGGG-CGACTTAACCTTAGGTTTTTG-30 was inserted into the
same vector. The G6PD sequence was made resistant to the G6PD shRNA by
introducing silent mutations (lower case: 50-GtTGATGAAGcGAGTGGGTTTC-30)
using the enzyme PrimeSTAR Max DNA Polymerase (Takara). Lentiviruses were
produced from these constructs using a three-plasmid packaging system as
described23. A549 cells were infected with the lentiviruses and selected for
monoclonal cells with green ﬂuorescence.
Analysis of G6PD glycosylation. Chemoenzymatic labelling and biotinylation of
proteins in cell lysates were carried out as described previously16 Brieﬂy, cell lysate
(500 mg) was labelled according to the Click-iT O-GlcNAc Enzymatic Labelling
System protocol (Invitrogen), and conjugated with an alkyne-biotin compound as
per the Click-iT Protein Analysis Detection Kit protocol (Invitrogen). Control
experiments were carried out in parallel in the absence of the labelling enzyme
GalT or UDP-GalNAz. Biotinylated lysates were precipitated using methanol and
chloroform as described in the Click-iT Protein Analysis Detection Kit protocol,
resolubilized in 1% SDS, and neutralized with an equal volume of neutralization
buffer (6% NP-40, 100mM Na2HPO4, 150mM NaCl). Lysates were then incubated
with strepavidin resin (Pierce) with end-to-end rotation at 4 C overnight. Resin
was then washed ﬁve times with 1ml of low-salt buffer (100mM Na2HPO4,
150mM NaCl, 0.1% SDS, 1% Triton X-100, 0.5% sodium deoxycholate) and ﬁve
times with 1ml of high-salt buffer (100mM Na2HPO4, 500mM NaCl, 0.2% Triton
X-100). Biotinylated proteins were eluted by boiling the resin in 50mM Tris-HCl
pH 6.8, 2.5% SDS, 100mM DTT, 10% glycerol and 20mM biotin for 10min.
Western blotting analysis was carried out with anti-G6PD or anti-Flag antibodies.
To quantify the level of glycosylation, the intensity of the total G6PD protein
band (Input) and the glycosylated G6PD protein band (Elution) were measured,
and the ratio of the intensity of the glycosylated protein versus the intensity of the
total protein was taken as the level of glycosylation.
G6PD puriﬁcation and enzymatic assays of G6PD and OGT. G6PD expression
constructs were individually transiently transfected into 293T cells and allowed for
expression for 48 h. To purify Flag-tagged G6PD, cells were lysed in Triton X-100
lysis buffer (50mM Tris-HCl, pH 7.4, 150mM NaCl, 1% Triton X-100, 5mM
thimet-G and Complete protease inhibitor cocktail). The lysate (7mg) was diluted
to 2mgml 1 with NETFS buffer (100mM NaCl, 50mM Tris-HCl pH 7.4, 5mM
EDTA, 5mM thiamet-G and Complete protease inhibitor cocktail). The sample
was incubated with anti-Flag M2 afﬁnity gel (400 ml; Sigma-Aldrich) at 4 C
overnight with end-to-end rotation. The gel was then washed twice with 10ml of
NETFS containing 1% Triton X-100, and twice with 10ml of NETFS. The Flag-
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G6PD protein was eluted with the 3 Flag peptide (Sigma-Aldrich) in NETFS
buffer according to the manufacturer’s protocol. The eluent was further puriﬁed
and concentrated using an Amicon Ultra Centrifugal Filter (10 kDa molecular
weight cutoff; Millipore) in a buffer containing 50mM Tris-HCl pH 7.5, 100mM
KCl, 5mM MgCl2 and 5% glycerol.
G6PD activity was measured using puriﬁed Flag-tagged G6PD in the reaction
buffer containing 55mM Tris-HCl pH 7.8, 3.3mM MgCl2, 6mM NADP, and
0.1M G6P. The reaction mixture was incubated at 30 C for 2minutes before
initiated by adding the G6PD enzyme (0.01mgml 1). Absorbance was recorded at
340 nm every 15 s for 10min using a UV–vis spectrophotometer (SHIMADZU
UV-2550). One unit of G6PD activity (IU) is deﬁned as the amount of enzyme that
catalyses the conversion of 1 mmol of NADP to NADPH per minute at 30 C. Since
absorbance DA (340 nm) of 1 mmolml 1 of NADPH is 6.22 in a 1-cm light path,
G6PD enzyme activity is calculated as:
Activity IUmg 1
  ¼ ðDAmin 1103Þð6:22mg enzyme per ml reaction mixtureÞ
Assays to determine steady-state kinetic parameters were performed in the above-
mentioned buffer with varying amounts of G6P and NADP. To ensure initial rate
measurements, the amount of G6PD was adjusted to give a linear increase in
readings within the ﬁrst 2min of the reaction. Kinetic parameters were calculated
using the equation as described35.
OGT activity was determined using a modiﬁed coupled enzyme assay as
described36 Cell lysates were concentrated to 10mgml 1 in centricon and used as
OGT enzyme source. Arbitrary absorbance was normalized to total protein
concentrations.
Hypoxic and glucose treatment. Hypoxia experiments were performed in a
sealed hypoxia chamber (Proox Model 110, BioSpherix, Ltd.) ﬁlled with 1% O2,
5% CO2, and 94% N2 at 37 C and 60% cell conﬂuency for the indicated periods of
time. For glucose treatment experiments, A549 stable rescue cells were seeded at a
density of 1 105 cells per ml in a 10-well tissue culture plate. The cells were
cultured in low glucose DMEM media (5mM glucose) for two passages before
switched to high glucose DMEM media (25mM glucose) for the indicated periods
of time.
Glucose uptake assay. Glucose uptake assay was performed using the Glucose
Uptake Fluorometric Assay Kit (BioVison) according to the manufacturer’s
instructions. Brieﬂy, cells were seeded at 2,500 cells per well at a 96-well tissue
culture plate. Cells were washed with phosphate-buffered saline (PBS) and incu-
bated in serum-free DMEM medium for 2 h, and further incubated in hypoxic
chambers for indicated periods of time. Cells were then quickly washed with PBS
and glucose uptake was initiated by incubating in KRPH buffer (20mM Hepes,
5mM KH2 PO4, 1mM MgSO4, 1mM CaCl2, 136mM NaCl, 4.7mM KCl, pH 7.4)
containing 10mM 2-deoxyglucose for 20min. Cells were then washed with PBS
three times and proceeded to oxidation step to generate recordable ﬂuorescence.
Arbitrary ﬂuorescence counts were normalized to total protein concentrations. For
inhibitor treatment, cells were pretreated with 100 mM phloretin for 30min before
incubated with 2-deoxyglucose.
Site mapping of G6PD glycosylation. Flag-tagged G6PD and HA-tagged OGT
were co-transfected in 293T cells. After 48 h, Flag-tagged G6PD was isolated using
anti-Flag M2 agarose beads as described above. The bound protein was eluted in a
buffer containing 4% SDS and 100mM Tris-HCl, pH 8.0. After SDS-PAGE (4–12%
Bis–Tris gels) and staining with Bio-Safe Coomassie blue R250 (0.25%) Stain
(Bio-Rad). The G6PD protein band was excised and manually digested in-gel with
trypsin. The extracted peptides were lyophilized and reconstituted in 1 binding
buffer (Glycoprotein Isolation Kit WGA, Thermo Scientiﬁc) and incubated with
WGA lectin resin (Glycoprotein Isolation Kit WGA, Thermo Scientiﬁc) at 4 C
with end-to-end rotation overnight. The resin was washed according to the
manufacturer’s protocol, and the bound peptides were eluted with the provided
elution buffer. The eluent was further puriﬁed by reverse-phase HPLC (Agilent
1100) using a preparative reverse-phase column (Agilent Eclipse XDB-C18; 5 mm,
9.4 250mm) and a gradient of 5–30% B buffer over 20min at 4mlmin 1
(A buffer, 0.5% aqueous AcOH; B buffer, 100% MeCN). Fractions eluting between
5–12min were collected, pooled, lyophilized and subjected to nanoLC-LTQ-CID/
ETD-MS analysis on an LTQ-Orbitrap Velos as previously described37. Data search
were performed by Proteome Discovery (MASCOT search engine, version 1.3)
with O-GlcNAc (Ser/Thr) set as variable modiﬁcation.
Analysis of the PPP activity. PPP activity was determined by following the
procedure as described23. Brieﬂy, 2 106 cells (WT or S84V G6PD A549
replacement cells, with or without OGT overexpression) were grown in a 6-cm
culture plate in sodium bicarbonate-free RPMI medium supplemented with
10% FBS, 20mM HEPES, 5mM glucose and 0.2 mCi of [1-14C]-glucose or [6-14C]-
glucose (American Radiolabeled Chemicals). The cells were placed in a closed glass
vial, the centre of which was covered with ﬁlter paper soaked in 100 ml of 5% KOH,
and incubated at 37 C for 4 h. The ﬁlter paper was removed and the radioactivity
was determined using a LS 6500 Multi-Purpose Scintillation Counter (Beckman
Coulter). PPP activity was calculated as the difference between the radioactivity
levels of samples obtained from [1-14C]-glucose and samples obtained from
[6-14C]-glucose, normalized to cell number.
Determination of PPP ﬂux by stable isotope labelling was followed as
described23. Brieﬂy, WT or S84V G6PD A549 replacement cells (with or without
OGT overexpression) were seeded at a concentration of 200,000 cells per well in a
6-well tissue culture plate and grown in complete RPMI 1640 culture medium for
24 h. Cells were pulse labelled in RPMI 1640 supplemented with 5mM [1,2-13C]-
glucose and 2mM glutamine for 4 h, and subjected to metabolite extraction with
80% aqueous methanol and dried by speedvac. Cell extracts were then analysed for
relative abundance of 13C-metabolites by liquid chromatography-triple quadrupole
mass spectrometry using scheduled selective reaction monitoring for each
metabolite of interest, with the detector set to negative mode as described23.
Extracted metabolite concentrations were calculated from standard metabolite
build-up curves using natural 12C synthetic metabolites and normalized against cell
number as well as the internal 13C-labelled metabolite standards added at the time
of metabolite extraction. Calculations for relative percentage of PPP ﬂux were as
described38.
Determination of NADPH and GSH levels. NADPH levels were determined
using a colorimetric NADPþ /NADPH Quantitation Kit (BioVision) according to
the manufacturer’s protocol. The signal at 450 nm was recorded using a Victor 3
microplate reader and normalized to protein concentration. GSH levels were
measured using a Glutathione Assay Fluorimetric Kit (Sigma-Aldrich) according to
the manufacturer’s procedure. Fluorimetric signal was recorded on a Victor 3
microplate reader and normalized to protein concentration.
LC–MS for metabolite analysis. The proﬁling of representative metabolites in
PPP, glycolysis and tricarboxylic acid cycle were carried out on an Xevo TQ-S
tandem mass spectrometer equipped with an electrospray source operating in the
negative-ion multiple-reaction monitoring mode. The ion source settings were as
follows: ion spray voltage,  3500V; source temperature, 120 C; desolvation gas,
cone gas and nebulizer gas at settings 600 l h 1, 150 l h 1 and 7 Bar, respectively.
Chromatographic separation was performed on a Phenomenex Luna Amide col-
umn (5mm, 100 2.0mm). The quantitative multiple-reaction monitoring tran-
sition of each particular metabolite was described as below, m/z 259497 for G6P;
m/z 259497 for fructose-6-phosphate (F6P); m/z 339497 for fructose-1,6-
diphosphate; m/z 169497 for dihydroxy-acetone-phosphate (DHAP) and glycer-
aldehyde-3-phosphate; m/z 185479 for 2-phosphoglycerate and 3-phosphoglyce-
rate (2PG/3PG); m/z 167479 for phosphoenolpyruvate; m/z 87443 for pyruvate;
m/z 808479 for acetyl-coenzyme A; m/z 1914111 for citrate; m/z 191473
for isocitrate; m/z 1454101 for 2-oxoglutarate; m/z 117473 for succinate;
m/z 115471 for fumarate; m/z 1334115 for malate; m/z 131487 for oxaloacetate;
m/z 173485 for cis-aconitate; m/z 275479 for 6-phosphogluconate; m/z 229497
for ribose-5-phosphate, ribulose-5-phosphate and xylulose-5-phosphate; m/z
289497 for sedoheptulose-7-phosphate; m/z 199497 for erythrose-4-phosphate.
Other MS/MS parameters, such as declustering potential and collision cell energy,
were optimized for each particular metabolite39. Data were acquired and processed
using MassLynx software (Version V4.1). Peak areas of individual metabolites were
normalized against the total protein amount. The fold changes of the relative level
of targeted metabolites are calculated (Data are presented as the mean±s.d. of
triplicate biological experiments). The mass spectrometry raw data have been
deposited in the iProX database.
Measurement of lipid synthesis. Cellular lipid synthesis was measured by
incorporation of 14C-glucose. Cells were seeded at subconﬂuency on a six-well
tissue culture plate. Cells were labelled with 4 mCiml 1 of 14C-glucose for 2 h,
followed by washing twice with cold PBS. Lipids in cells were extracted with 800 ml
of hexane:isopropanol (3:2, v/v). Extracts were dried by speedvac, resuspended in
50 ml of chloroform, and subjected to scintillation counting. Counts were nor-
malized with cell numbers.
Measurement of ROS levels and H2O2-mediated cell death. A redox-sensitive
dye 5(6)-chloromethyl-2’7’-dichlorodihydroﬂuorescein diacetate-acetyl ester
(CM-H2DCFDA; Molecular Probes) was used to measure ROS levels in cell lines as
previously described23. Brieﬂy, cells were cultured overnight at a density of 4 105
cells per well in a 12-well tissue culture plate in complete DMEM media. After
treating cells with various concentrations of diamide (Sigma-Aldrich) as indicated
for 10min, fresh culture media were added. The cells were then incubated with
10 mM CM-H2DCFDA for 20min and rinsed three times with PBS. The cells were
lysed in 1% SDS and sonicated. The mixture was centrifuged (15,000 g, 2min) to
remove any cell pellets. 100-ml aliquots were taken, and the ﬂuorescent intensity
was measured on a Victor 3 microplate reader. Signal intensity was normalized to
protein concentration.
The percentage of cell death was measured using a lactate dehydrogenase
(LDH)-based toxicology assay kit (Sigma-Aldrich) according to the manufacturer’s
protocol. The percentage of cell death was determined by comparing the amount of
cytoplasmic LDH released into the culture medium relative to the total cytoplasmic
LDH, as determined by the reduction of NADþ .
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Cell proliferation analysis. Cell proliferation assays were performed by seeding
2,000 cells per well in a 96-well tissue culture plate in normoxia. Twenty-four hours
after seeding, cells that were used for hypoxic treatments were further cultured in
the sealed hypoxic chamber as mentioned above. Cell proliferation was determined
by counting cell numbers as stained by trypan blue every 24 h for 96 h.
Xenograft studies. Immunocompromised mice (BALB/c-nude, male, 5–6 week
old, Charles River Laboratories) were injected subcutaneously with 4.5 106 cells
each (resuspended in 100ml of serum-free F12-K medium) in the right ﬂank (WT
G6PD A549 replacement cells) and the left ﬂank (S84V G6PD A549 replacement
cells). Tumor growth was monitored every 3 days over a 7-week period. At the end
of the seventh week, the tumours were harvested and weighed. Experiments were
performed in accordance with the Zhejiang University Institutional Animal Care
and Use Committee guidelines.
Statistical analysis. P values were calculated from Student’s paired t-test when
comparing within groups and from Student’s unpaired t-test when comparing
between groups. For those analyses where more than one t-test is applied to the
same data set, statistical analysis was performed by one-way analysis of variance
and Bonferroni comparison post-test.
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